Treatment Decisions for R/R Multiple Myeloma
Symposium
Symposium

Treatment Decisions for R/R Multiple Myeloma

Fitting the Pieces Together

Not a member of My prIME? Join now for instant access.

Meeting Overview

Enhance your understanding of the treatment of patients with relapsed/refractory multiple myeloma (R/R MM) with a focus on immunotherapy along with treatment selection and sequencing in the R/R disease setting. In addition to a short didactic lecture on the evolving role of immunotherapy in multiple myeloma, real-life clinical scenarios in the R/R setting will be presented and examined during a faculty panel discussion.

A satellite symposium in association with the 1st European Myeloma Network (EMN) Meeting.

Date and Location

Friday, 20 April 2018
14.30 – 16.00

Auditorium Agnelli
Lingotto Conference Center
Via Nizza, 280
Turin, Italy

Date/Time

Date/Time

Friday, 20 April 2018
14.30 – 16.00

Location

Location

Turin, Italy

CME

CME

1.5 AMA PRA Category 1 Credits

14.30 Welcome and introduction
Pieter Sonneveld, MD, PhD
14.35 Pop quiz on R/R MM
Pieter Sonneveld, MD, PhD
14.40 Hot topic in MM: The evolving role for immunotherapy in patients with R/R disease
Gareth Morgan, MD, PhD, FRCP, FRCPath
14.55 Questions from the audience
15.00 Weighing the options at first relapse
Hermann Einsele, MD
15.15 Questions from the audience
15.20 How do I choose?: Treatment decisions after multiple lines of therapy
Meletios Dimopoulos, MD
15.35 Questions from the audience
15.40 Burning questions and future directions in R/R MM: A panel discussion with the experts
Moderator: Pieter Sonneveld, MD, PhD
15.55 Post-activity quiz and prIME Points™
Pieter Sonneveld, MD, PhD
16.00 Adjourn

    Chair

  • Pieter Sonneveld, MD, PhDErasmus Medical Center Cancer Institute
    Rotterdam, the Netherlands
  • Faculty

  • Meletios Dimopoulos, MDUniversity of Athens
    Athens, Greece
  • Hermann Einsele, MDJulius Maximilian University of Würzburg
    Würzburg, Germany
  • Gareth Morgan, MD, PhD, FRCP, FRCPathUniversity of Arkansas for Medical Sciences
    Little Rock, Arkansas, United States

This activity is intended for hematologists, oncologists and other healthcare professionals involved in the management of patients with MM.

After successful completion of this educational activity, participants should be able to:

  • Discuss the rationale and mechanism of action for emerging immunotherapy options in the treatment of R/R MM
  • Evaluate recent clinical trial data investigating the efficacy and safety of novel doublet and triplet treatment regimens and employ best practices in the selection of these regimens in the treatment of R/R MM
  • Describe the factors that influence treatment selection and sequencing in the R/R disease setting
  • Identify important ongoing clinical trials investigating novel treatment approaches for R/R MM

This educational activity is supported by a grant from Bristol-Myers Squibb.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Treatment Decisions for R/R Multiple Myeloma - prIME Oncology

prIME Oncology designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Good CME

Treatment Decisions for R/R Multiple Myeloma - prIME Oncology

Provider

This activity is provided by prIME Oncology.

Sunshine Act/EFPIA

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.

Disclosures

Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.